IL214211A0 - Stable vaccine compositions and methods for preparing the same - Google Patents
Stable vaccine compositions and methods for preparing the sameInfo
- Publication number
- IL214211A0 IL214211A0 IL214211A IL21421111A IL214211A0 IL 214211 A0 IL214211 A0 IL 214211A0 IL 214211 A IL214211 A IL 214211A IL 21421111 A IL21421111 A IL 21421111A IL 214211 A0 IL214211 A0 IL 214211A0
- Authority
- IL
- Israel
- Prior art keywords
- preparing
- methods
- same
- vaccine compositions
- stable vaccine
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/07—Bacillus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55505—Inorganic adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55561—CpG containing adjuvants; Oligonucleotide containing adjuvants
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Biochemistry (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Inorganic Chemistry (AREA)
- Immunology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Molecular Biology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
PCT/GB2009/050051 WO2010084298A1 (en) | 2009-01-22 | 2009-01-22 | Stable vaccine compositions and methods of use |
Publications (1)
Publication Number | Publication Date |
---|---|
IL214211A0 true IL214211A0 (en) | 2011-08-31 |
Family
ID=41082348
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
IL214211A IL214211A0 (en) | 2009-01-22 | 2011-07-20 | Stable vaccine compositions and methods for preparing the same |
Country Status (6)
Country | Link |
---|---|
EP (1) | EP2381959A1 (en) |
JP (1) | JP2012515752A (en) |
AU (1) | AU2009338516A1 (en) |
CA (1) | CA2750321A1 (en) |
IL (1) | IL214211A0 (en) |
WO (1) | WO2010084298A1 (en) |
Families Citing this family (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
SG10202012986SA (en) | 2006-09-29 | 2021-01-28 | Ligocyte Pharmaceuticals Inc | Norovirus vaccine formulations |
SG184733A1 (en) | 2007-09-18 | 2012-10-30 | Ligocyte Pharmaceuticals Inc | Method of conferring a protective immune response to norovirus |
AU2009299615B2 (en) | 2008-10-02 | 2015-07-16 | Pharmathene Inc. | Anthrax vaccine formulation and uses thereof |
CN105031637A (en) * | 2011-07-11 | 2015-11-11 | 武田疫苗股份有限公司 | Parenteral norovirus vaccine formulations |
SG11201408262XA (en) * | 2012-06-25 | 2015-01-29 | Emergent Product Dev Gaithersburg Inc | Temperature stable vaccine formulations |
US10357559B2 (en) | 2013-12-27 | 2019-07-23 | Emergent Product Development Gaithersburg Inc. | Temperature stable vaccine formulations |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1592443B1 (en) * | 2003-02-13 | 2011-03-30 | Becton, Dickinson and Company | Improved anthrax vaccines and delivery methods |
EP2068834A2 (en) * | 2006-09-08 | 2009-06-17 | Becton, Dickinson & Company | Stable powder formulations of aluma-dsorbed vaccines |
EP1972347A1 (en) * | 2007-03-19 | 2008-09-24 | Becton, Dickinson and Company, Wagner, Jaconda | Stable vaccine powder formulations |
GB0801122D0 (en) * | 2008-01-22 | 2008-02-27 | Avecia Biolog Ltd | Vaccine composition |
-
2009
- 2009-01-22 AU AU2009338516A patent/AU2009338516A1/en not_active Abandoned
- 2009-01-22 EP EP09785211A patent/EP2381959A1/en not_active Withdrawn
- 2009-01-22 CA CA2750321A patent/CA2750321A1/en not_active Abandoned
- 2009-01-22 JP JP2011546933A patent/JP2012515752A/en active Pending
- 2009-01-22 WO PCT/GB2009/050051 patent/WO2010084298A1/en active Application Filing
-
2011
- 2011-07-20 IL IL214211A patent/IL214211A0/en unknown
Also Published As
Publication number | Publication date |
---|---|
AU2009338516A1 (en) | 2011-08-18 |
WO2010084298A1 (en) | 2010-07-29 |
JP2012515752A (en) | 2012-07-12 |
CA2750321A1 (en) | 2010-07-29 |
EP2381959A1 (en) | 2011-11-02 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
PT2574187T (en) | Squalane and isosqualane compositions and methods for preparing the same | |
ZA201006944B (en) | Compositions and methods for preparing and using same | |
GB201003924D0 (en) | Immunogenic composition | |
HK1167107A1 (en) | Vaccine composition comprising 5-cap modified rna 5-cap rna | |
GB0913681D0 (en) | Immunogenic composition | |
IL223206A0 (en) | Vaccine formulations | |
IL217375A (en) | Methods for preparing vesicles and formulations produced therefrom | |
GB201015132D0 (en) | Vaccine composition | |
IL242592A (en) | Immunogenic compositions | |
PT2402032T (en) | Immunogenic composition | |
EP2285405A4 (en) | Vaccine compositions and methods | |
EP2515940A4 (en) | Immunogenic compositions and related methods | |
GB201005625D0 (en) | Immunogenic proteins and compositions | |
HK1213594A1 (en) | Immunogenic compositions and uses thereof | |
GB201103423D0 (en) | Immunogenic proteins and compositions | |
EP2609931A4 (en) | Immunogenic composition | |
IL214127A0 (en) | Vaccine compositions | |
IL214211A0 (en) | Stable vaccine compositions and methods for preparing the same | |
EP2252326A4 (en) | Vaccine compositions | |
EP2498815A4 (en) | Vaccine composition | |
GB0913680D0 (en) | Immunogenic composition | |
IL220308A0 (en) | Vaccine compositions | |
EP2640418A4 (en) | Immunogenic compositions | |
EP2496593A4 (en) | Amphiphilic compositions and methods for preparing and using same | |
ZA201301908B (en) | Immunogenic compositions |